SCHEDULE: Armistice Capital Discloses BioXcel Therapeutics Stake

Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, reporting beneficial ownership of 4.99% of BioXcel Therapeutics, Inc. common stock as of June 30, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have jointly filed an amended Schedule 13G, indicating their beneficial ownership of BioXcel Therapeutics, Inc. common stock.
• As of June 30, 2026, the reporting persons collectively beneficially owned 1,621,716 shares, representing 4.99% of the class of securities.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, may be deemed to beneficially own the shares held by the Master Fund.
• The filing states that the Master Fund disclaims beneficial ownership due to the investment management agreement with Armistice Capital.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral filing, primarily a routine disclosure of beneficial ownership exceeding 5% by an investment manager and its principal. It does not contain operational or financial performance updates.

Positives

• The filing clearly delineates the ownership structure and reporting responsibilities.
• The percentage of ownership (4.99%) is just below the 5% threshold that would trigger more stringent reporting requirements.

Negatives

• No operational or financial performance data is provided in this filing.
• The filing does not offer insights into the investment strategy or rationale behind the stake.

Risks

• Potential for increased scrutiny or future disclosure requirements if ownership crosses the 5% threshold.
• Market perception of increased institutional interest, which could lead to volatility.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance.

Management Comments

• Armistice Capital, LLC exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment managers accumulating significant stakes in public companies. This filing indicates a notable position by Armistice Capital in BioXcel Therapeutics, a biotechnology firm.

Stakeholder Impact

• Shareholders may view this as increased institutional interest, potentially influencing stock price.
• Management may need to engage with Armistice Capital regarding their investment strategy.

Next Steps

• Continued monitoring of Armistice Capital's ownership stake in BioXcel Therapeutics.
• Potential for future amendments to the Schedule 13G if ownership levels change.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Investment Management, Armistice Capital, BioXcel Therapeutics, Securities Exchange Act